Disease free survival and overall survival from Holliday Junction Recognition Protein (HJURP) expression in non-metastatic breast cancer patients

Wirsma Arif Harahap; Ari Oktavenra; Rony Rustam; Rhandyka Rafli; Hardisman Hardisman

doi:10.23750/abm.v95i1.13619

Disease free survival and overall survival from Holliday Junction Recognition Protein (HJURP) expression in non-metastatic breast cancer patients

Authors

Wirsma Arif Harahap Andalas University
Ari Oktavenra Andalas University https://orcid.org/0000-0002-0380-3293
Rony Rustam Andalas University
Rhandyka Rafli Andalas University
Hardisman Hardisman Andalas University

DOI: https://doi.org/10.23750/abm.v95i1.13619

Keywords:

Breast Cancer, Disease Free Survival, HJURP, Overall Survival, Radiotherapy Interruptions

Abstract

Background and aim: Holliday Junction Recognition Protein (HJURP) is a gene that integrates with Centromere Protein A (CENPA) which plays a role in cell proliferation. It is related to radiation response where high HJURP level give a good response to radiotherapy and a high rate of apoptosis. It is a prognostic factor for Disease Free Survival (DFS) and Overall Survival (OS) and a predictive biomarker on radiotherapy. This study aimed to analyze the correlation between HJURP expression with DFS and OS in breast cancer patients who received radiotherapy. Methods: This study used a quantitative method with a cross-sectional design. Data were collected from 57 non-metastatic breast cancer patients undergoing radiotherapy from 2019 to 2021. Patients were examined from paraffin blocks by IHC examination using HJURP antibodies which were then assessed for expression. Data were analyzed using survival analysis with Kaplan-Meier and Cox Regression test. Results: The majority of breast cancer patients who received radiotherapy had positive HJURP expression (68.4%). There was no statistically significant correlation between HJURP expression with DFS or OS in breast cancer patients who received radiotherapy. However, there was a statistically significant correlation between radiotherapy interruptions and OS where patients with interruptions >3 times had a risk of death 8.40 times faster than patients with interruptions ≤3 times (95% confidence interval [CI]). Conclusions: Although HJURP expression was not related with survival in breast cancer patients who received radiotherapy, it is a good candidate as a predictive biomarker of radiotherapy response.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: https://doi.org/10.3322/caac.21492.

de Oca RM, Gurard-Levin ZA, Berger F, et al. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Mol Oncol 2015; 9: 657-74. doi: https://doi.org/10.1016/j.molonc.2014.11.002.

Hu Z, Huang G, Sadanandam A, et al. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res 2010; 12: 1-5. doi: https://doi.org/10.1186/bcr2487.

Kadarullah O. [Intensity of radiotherapy in head and neck malignancies]. Indonesia: Hasan Sadikin Hospital; 2012. p. 22.

Yao JJ, Jin YN, Wang SY, et al. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC Cancer 2018; 18: 1-7. doi: https://doi.org/10.1186/s12885-018-4495-2.

Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery 2002; 132: 620-7. doi: https://doi.org/10.1067/msy.2002.127544.

Fesinmeyer MD, Mehta V, Blough D, Tock L, Ramsey SD. Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 78: 675-81. doi: https://doi.org/10.1016/j.ijrobp.2009.08.004.